Anavex Life Sciences Releases Encouraging Long Term Data From Rett Syndrome Study
Portfolio Pulse from Vandana Singh
Anavex Life Sciences Corp announced that long-term clinical study results from the U.S. ANAVEX2-73-RS-001 study demonstrate a disease-modifying effect of ANAVEX2-73 (blarcamesine) for adult patients with Rett syndrome. The data shows that blarcamesine exhibited both symptomatic and disease-modifying effects for Rett syndrome in a clinical setting. Despite the positive news, AVXL shares are down 1.67% at $7.95 on the last check Wednesday.
June 28, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Anavex Life Sciences Corp's long-term clinical study results show a disease-modifying effect of ANAVEX2-73 for adult patients with Rett syndrome. Despite the positive news, AVXL shares are down 1.67%.
The positive long-term clinical study results are a significant development for Anavex Life Sciences Corp. However, despite the encouraging results, the company's stock price has fallen, indicating that the market may have already priced in the positive news or there are other factors at play affecting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100